Also, it seems unlikely that eradication of the MPN clone can be achieved with the available JAK2 inhibitors, as suggested by the inability of the JAK2 inhibitor TG101348 12 to affect the disease-initiating cell population in JAK2V617F KI mice; therefore novel drugs and/or more effective therapeutic strategies need to be sought. Here, JAK2 is linked to myeloproliferative disorder.